Drug intelligence / Profile preview

68Ga-GP-01

Development stage: Phase 1
Lead developer: Grand Pharmaceutical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-GP-01 is a radiopharmaceutical agent designed for positron emission tomography (PET) imaging in oncology. It consists of the radioactive isotope gallium-68 (^68Ga^) conjugated to a ligand that targets fibroblast activation protein (FAP), a protein commonly found in high amounts in various tumor tissues. By binding to FAP-expressing cells, 68Ga-GP-01 allows for the visualization of tumors and potentially aids in cancer diagnosis, staging, and treatment planning. It is currently under clinical investigation, particularly in patients with solid tumors[5][6][7][8].

Brand names: 68Ga-GP-01
Other names: 68Ga-GP-01 Injection[68Ga]Ga-GP-01

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 68Ga-GP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-GP-01.

Explore the full profile